Open main menu

Psychiatrienet β

Duloxetine-hypericum

Revision as of 11:29, 4 November 2015 by Anoek (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from duloxetine to hypericum.[1] [2]

Nietinrijdenbord.png Stop duloxetine
  • Before day 1: gradually reduce dosage of duloxetine to a maximum of 60 mg/ day, when this dosage is > 60 mg/day.
  • Day 1: reduce dosage of duloxetine to a maximum of 30 mg/day.
  • Day 8: stop administration of duloxetine.
Eenrichtingbord.png Start hypericum
  • Day 8-12: a wash-out period is necessary.
  • Day 13: start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).[3] [4][5][6]
Letopbord.png Cave
Infobord.png More information
  • Hypericum induces enzymes of the CYP P-450 type and P-gp type.
  • Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
  • Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[7]
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.